Figure 4

Prognostic impact of NS status in the three subgroups of the different biological subtype tumors: luminal-type tumors, HER2-type tumors, and triple-negative tumors. A. Subgroup analysis of the 154 patients with luminal-type tumors (HR-positive tumors). Two disease-free survival (DFS) curves, that for the 102 patients with NS-positive tumors and that for the 52 patients with NS negative tumors, differ significantly (P = 0.033). B. Subgroup analysis of the 22 patients with HER2-type tumors (HER2-positive and HR-negative tumors). In two disease-free survival (DFS) curves, that for the 18 patients with NS-positive tumors and that for the 4 patients with NS-negative tumors, five-year DFS rates differ largely (100% vs 28%). P-value was not available because there was no relapse in the patients with NS-negative tumors. C. Subgroup analysis of the 44 patients with triple-negative tumors (HR and HER2 negative tumors). The two curves do not differ significantly (P = 0.41).